The Robert A. Winn Diversity in Clinical Trials: Clinical Investigator Leadership Award powered by Conquer Cancer’s EveryGrant® (Winn CILA-Onc) is a three-year career and leadership development program designed to provide clinical cancer investigators with advanced clinical trials knowledge, leadership skills, mentorship and sponsorship to succeed as independent clinical researchers, team members, and leaders.
The leadership and training program will be led by the American Society of Clinical Oncology and funded by the Bristol Myers Squibb Foundation and includes collaboration with the members of the National Cancer Institute’s National Clinical Trials Network (NCTN). The program launched in early 2024 and will continue for five years, with the goal of training a total of 25 clinical trialists over a seven-year period. The program will provide salary support for the participants during their award term, support for the NCTN cooperative groups, and other training-related costs.
Eligibility Criteria
Applicants must meet the following criteria:
- Be a current or immediate past Robert A. Winn Career Development Award Scholar who has or will complete the Winn CDA term by December 2024
- Completed an oncology subspeciality training.
- Be employed by an institution that is a current/active member of an NCI National Clinical Trials Network.
- Be able to commit at least 30% of full- time effort in during the award period, as confirmed in an institutional Letter of Support.
Application Instructions
The Full Application must be submitted in accordance with the requirements and instructions in the Request for Applications by the submission deadline. All application materials must be submitted electronically through Conquer Cancer’s Application Portal. Paper applications or applications sent by e-mail or fax will not be accepted. Questions can be addressed to the ASCO Professional Development team.
Key Dates
Application Opens: April 15, 2024 (Cohort 2)
Application Deadline: June 17, 2024 by 11:59 PM ET
Notification Date: September 2024
Award Term: January 1, 2025 – December 31, 2027
Announcements
Recipients
Cohort 1
Fiorella Iglesias Cardenas, MD, MS
Memorial Sloan Kettering Cancer Center
NCTN Cooperative Group: Children’s Oncology Group
Luis Malpica Castillo, MD
The University of Texas MD Anderson Cancer Center
NCTN Cooperative Group: SWOG Cancer Research Network
Catherine Marshall, MD, MPH
Johns Hopkins University
NCTN Cooperative Group: ECOG-ACRIN Cancer Research Group
Oluwadamilola Oladeru, MD, MA, MBA
Mayo Clinic, Florida
NCTN Cooperative Group: Alliance for Clinical Trials in Oncology
Sherise Rogers, MD, MPH
University of Florida
NCTN Cooperative Group: NRG Oncology
To learn more about the Robert A. Winn Diversity in Clinical Trials Award Program, please visit the program’s website at diversityinclinicaltrials.org.
This program is funded by